Date: 2018-09-13
Type of information: Resignation
Compound:
Company: Lysogene (France)
Therapeutic area: Rare diseases - Genetic diseases
Type agreement: resignation
Action mechanism:
Disease:
Details:
- • On September 13, 2018, Lysogene announced that it has been informed of the resignation of Bpifrance Investissement from its mandate as director of the company. The permanent representative of Bpifrance Investissement within the Board of Directors is replaced at the Audit Committee by Mr. Peter Lichtlen, independent member of Lysogene's Board of Directors.
Financial terms:
Latest news:
Is general: Yes
